BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 22820542)

  • 1. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
    Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
    Nishijima T; Hamada Y; Watanabe K; Komatsu H; Kinai E; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    PLoS One; 2013; 8(10):e77268. PubMed ID: 24130871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
    Rockwood N; Mandalia S; Bower M; Gazzard B; Nelson M
    AIDS; 2011 Aug; 25(13):1671-3. PubMed ID: 21716074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
    Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
    Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
    Hamada Y; Nishijima T; Komatsu H; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    PLoS One; 2013; 8(7):e69845. PubMed ID: 23875004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
    Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.
    Monforte Ad; Reiss P; Ryom L; El-Sadr W; Dabis F; De Wit S; Worm SW; Law MG; Weber R; Kirk O; Pradier C; Phillips AN; Lundgren JD; Sabin CA
    AIDS; 2013 Jan; 27(3):407-15. PubMed ID: 23291539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
    Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
    HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical utility of atazanavir].
    Ribera Pascuet E; Curran A
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():55-67. PubMed ID: 20116619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
    Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
    Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.
    Moyle GJ; Andrade-Villanueva J; Girard PM; Antinori A; Salvato P; Bogner JR; Hay P; Santos J; Astier L; Pans M; Balogh A; Biguenet S;
    Antivir Ther; 2012; 17(4):689-700. PubMed ID: 22388634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of renal stones in patients treated with atazanavir.
    Tattevin P; Revest M; Chapplain JM; Ratajczak-Enselme M; Arvieux C; Michelet C
    Clin Infect Dis; 2013 Apr; 56(8):1186. PubMed ID: 23300244
    [No Abstract]   [Full Text] [Related]  

  • 18. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
    Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
    Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T
    HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.